Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application
Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application covers the use of Quantison for left ventricular opacification as well as myocardial perfusion indications. Quantison consists of air-filled albumin microcapsules developed for intravenous imaging (SCAN 2/5/97).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.